(HealthDay)—Exposure to paclitaxel in drug-coated balloons used in procedures for the treatment of symptomatic femoropopliteal peripheral arterial disease is not associated with mortality, according to a study published ...
Jan 28, 2019
0
2
Researchers in Brazil have discovered a new effect of a drug widely used as a chemotherapeutic agent and offered to patients free of charge by SUS, the national health service.
Oct 25, 2018
0
2
(HealthDay)—For patients with previously treated advanced gastric cancer or gastro-esophageal junction cancer, pembrolizumab does not result in a significant improvement in overall survival compared with paclitaxel, according ...
Jul 3, 2018
0
3
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.
Feb 23, 2018
0
294
European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be ...
Sep 4, 2017
0
1
A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's attack on tumors back into the kind that amplify it. This is the finding of a study led ...
Feb 10, 2017
0
109
MIT biologists have identified a new biomarker that can reveal whether patients with a particularly aggressive type of breast cancer will be helped by paclitaxel (commercially known as Taxol), one of the drugs most commonly ...
Nov 22, 2016
0
83
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...
Aug 18, 2016
0
0
New research indicates that paclitaxel, which is the most commonly used chemotherapy for breast cancer, suppresses tumors when given at a certain dosage, but at low doses, it actually promotes cancer spread to the liver.
Jun 22, 2016
0
14
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination ...
Apr 18, 2016
0
15
